by Alicen Baran | May 13, 2021 | News
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals announced the launch of Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥. “The launch of Succinylcholine Chloride represents Nexus...
by Deana Mndrucic | Mar 28, 2021 | News, Product Approvals
LINCOLNSHIRE, Ill.–Nexus Pharmaceuticals announced today that it has received U.S. Food and Drug Administration (FDA) approval for Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, 20mEq/100mL, 40mEq/100mL and 20mEq/50mL Single-Dose IV bags....
by Deana Mndrucic | Mar 23, 2021 | News
LINCOLNSHIRE, Ill.–Nexus Pharmaceuticals, Inc. is pleased to announce that it has received authorization to occupy its new pharmaceutical manufacturing facility from the Village of Pleasant Prairie, Wisconsin. Nexus Pharmaceuticals, which specializes in...
by Deana Mndrucic | Jan 27, 2021 | News
PLEASANT PRAIRIE, WI.–Nexus Pharmaceuticals Chief Strategy Officer, Omair Ahmed, joined nine BioForward member organizations in a discussion regarding the Wisconsin biohealth industry’s response to the COVID-19 pandemic. “We pride ourselves in...
by Deana Mndrucic | Dec 21, 2020 | News
PLEASANT PRAIRIE, WI.–Nexus Pharmaceuticals Inc. plans to complete its nearly $100 million Pleasant Prairie sterile injectables plant in April 2021 and a company executive said it will help address the United States’ reliance on foreign pharmaceutical suppliers...
by Deana Mndrucic | Dec 3, 2020 | News
LINCOLNSHIRE, Ill.–Nexus Pharmaceuticals is pleased to announce their continuous certification as a Minority Business Enterprise (MBE) and a Women’s Business Enterprise (WBE). The diversity-based certifications, appointed by the National Minority Supplier...
